MULTIPLE MYELOMA AND OTHER PLASMA CELL DISEASES

multiplemyelomawos

FIRST LINE TREATMENTIN NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA

Yaşa Gül Mutlu1 Senem Maral2

1Gaziantep City Hospital, Department of Hematology, Gaziantep, Türkiye
2İstanbul Medipol University, Faculty of Medicine, Department of Hematology, İstanbul, Türkiye

Mutlu YG, Maral S. First Line Treatment in Newly Diagnosed Transplant Eligible Multiple Myeloma. In: Sevindik ÖG, editor. Multiple Myeloma and Other Plasma Cell Dyscrasias. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.41-44.

ABSTRACT

First-line treatment is crucial for optimizing progression-free survival (PFS) and overall survival (OS) in Multiple Myeloma (MM), guided by patient-specific factors such as age, comorbidities, and transplant eligibility. For transplant-eligible patients, induction with quadruplet regimens—comprising a proteasome inhibitor, immunomodulatory agent, anti-CD38 monoclonal antibody, and steroid—has demonstrated superior outcomes in stringent complete response (sCR), minimal residual disease (MRD) negativity, and PFS compared to triplet regimens. Autologous stem cell transplantation (ASCT) remains a cornerstone of therapy, offering significant PFS benefits, with studies like DETERMINATION and IFM 2009 highlighting flexible timing options. Tailored first-line strategies are essential to ensure optimal disease control and improved quality of life in MM.

Keywords: Multiple myeloma; First line treatment; Transplant eligible; Quadruplets; Newly diagnosed

Referanslar

  1. Isaacs A, Fiala M, Tuchman S, Wildes TM. A comparison of three different approaches to defining frailty in old- er patients with multiple myeloma. J Geriatr Oncol 2020; 11(2): 311-315. e-pub ahead of print 2019/07/22; [Crossref]  [PubMed]  [PMC]
  2. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an Internation- al Myeloma Working Group report. Blood 2015; 125(13): 2068-2074. e-pub ahead of print 2015/01/30; blood-2014-12-615187.
  3. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bor- tezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020; 136(8): 936-945. e-pub ahead of print 2020/04/24; [Crossref]  [PubMed]  [PMC]
  4. Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and borte- zomib in transplant-ineligible multiple myeloma: the ran- domized phase 3 BENEFIT trial. Nat Med 2024; 30(8): 2235-2241. e-pub ahead of print 2024/06/04; s41591-024-03050-2.
  5. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Ben- boubker L, et al. Bortezomib, thalidomide, and dexametha- sone with or without daratumumab before and after autolo- gous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019; 394(10192): 29-38. e-pub ahead of print 2019/06/07; [Crossref]  [PubMed]
  6. Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexa- methasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017; 389(10068): 519-527. e-pub ahead of print 2016/12/27; [Crossref]  [PubMed]
  7. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bah- lis N, et al. Daratumumab plus Lenalidomide and Dexa- methasone for Untreated Myeloma. N Engl J Med 2019; 380(22): 2104-2115. e-pub ahead of print 2019/05/30; [Crossref]  [PubMed]  [PMC]
  8. Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDUR- ANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020-21(10): 1317-1330. e-pub ahead of print 2020/09/01 [Crossref]  [PubMed]
  9. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexa- methasone with Transplantation for Myeloma. N Engl J Med 2017; 376(14): 1311-1320. e-pub ahead of print 2017/04/06; [Crossref]  [PubMed]  [PMC]
  10. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lo- nial S, Raje NS, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med 2022; 387(2): 132-147. e-pub ahead of print 2022/06/07; [Crossref]  [PubMed]  [PMC]